No differences were identified in the proportion of IFN-γ- or IL-17-expressing cells following baricitinib treatment in SLE or HC in any cell subset following IL-6 or IL-15 stimulation (Supplementary Figure 1). This evidence concerns the gene IL6 and systemic lupus erythematosus.